Anaemetro I.V. Infusion 500mg Drug Use Investigation

N/ACompletedNCT03491228

Pfizer107 enrolled

Overview

Secondary Data Collection Study; safety and effectiveness of Anaemetro under Japanese medical practice

Study Type

OBSERVATIONAL

Enrollment

107

Conditions

Anaerobic Infection Infectious Enterocolitis Amebic Dysentery

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who have not used metronidazole (injection) in the past, and have been given this drug for treatment of anaerobic infection, infectious enterocolitis, or amebic dysentery. Patients who have used metronidazole (oral agent and vaginal tablet) in the past are eligible, and should not be excluded from this study. Exclusion Criteria: * No exclusion criteria are set out in this study.

Outcomes

Primary Outcomes

Number of Participants With Adverse Drug Reaction (ADR)

An adverse drug reaction (ADR) was any untoward medical occurrence attributed to ANAEMETRO Intravenous infusion in a participant who received ANAEMETRO Intravenous infusion. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Relatedness to ANAEMETRO Intravenous infusion was assessed by the physician.

Time frame: Maximum 8 weeks

Secondary Outcomes

Clinical Response Rate

Time frame: Maximum 8 weeks

Clinical Response Rates by Target Diseases

Clinical response of ANAEMETRO Intravenous infusion was evaluated comprehensively at the completion of the observation period, being assessed as "effective," "not effective," or "indeterminate" by the physician based on clinical symptoms. Clinical response rate, which was defined as the percentage of participants evaluated as "effective" over the total number of assessable effectiveness analysis population, was presented along with the corresponding 2-sided 95% CI. Participants assessed as "effective" by the following target diseases were counted to assess whether they contribute to the clinical response: anaerobic infection, infectious enterocolitis, amebic dysentery, and the infection with both infectious enterocolitis and amebic dysentery.

Time frame: Maximum 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.